Dr. Fran Gregory's Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
Season 6, Episode 17, Sep 17, 2023, 11:00 PM
On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
To read more about Dr. Gregory's commentary piece, click here.
To read more about Cardinal Health's 2023 Biosimilars Report, click here.
To learn more about adalimumab biosimilars, click here.
To learn more about the adalimumab biosimilars that have launched so far in the US:
To read more about Cardinal Health's 2023 Biosimilars Report, click here.
To learn more about adalimumab biosimilars, click here.
To learn more about the adalimumab biosimilars that have launched so far in the US:
- Click here for the launch of Amjevita
- Click here for the launches of Hyrimoz, Hadlima, Yusimry, and Cyltezo
- Click here for the launch of Yuflyma
- Click here for the launches of Idacio and Hulio